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Abstract
Remote ischemic preconditioning (RIPC) offers cardioprotection against myocardial ischemia–reperfusion injury. The 
humoral factors involved in RIPC that are released from parasympathetically innervated organs have not been identified. 
Previous studies showed that ghrelin, a hormone released from the stomach, is associated with cardioprotection. However, 
it is unknown whether or not ghrelin is involved in the mechanism of RIPC. This study aimed to determine whether ghrelin 
serves as one of the humoral factors in RIPC. RIPC group rats were subjected to three cycles of ischemia and reperfusion 
for 5 min in two limbs before left anterior descending (LAD) coronary artery ligation. Unacylated ghrelin (UAG) group rats 
were given 0.5 mcg/kg UAG intravenously 30 min before LAD ligation. Plasma levels of UAG in all groups were measured 
before and after RIPC procedures and UAG administration. Additionally, JAK2/STAT3 pathway inhibitor (AG490) was 
injected in RIPC and UAG groups to investigate abolishment of the cardioprotection of RIPC and UAG. Plasma levels of 
UAG, infarct size and phosphorylation of STAT3 were compared in all groups. Infarct size was significantly reduced in 
RIPC and UAG groups, compared to the other groups. Plasma levels of UAG in RIPC and UAG groups were significantly 
increased after RIPC and UAG administration, respectively. The cardioprotective effects of RIPC and UAG were accompanied 
by an increase in phosphorylation of STAT3 and abolished by AG490. This study indicated that RIPC reduces myocardial 
ischemia and reperfusion injury through UAG-induced activation of JAK/STAT pathway. UAG may be one of the humoral 
factors involved in the cardioprotective effects of RIPC.
Keywords Remote ischemic preconditioning · Myocardial ischemia reperfusion injury · Ghrelin · Preconditioning
Introduction
Globally, the number of age-related diseases has tended 
to increase annually along with longer human lifespans. 
Ischemic heart disease is globally recognized as a life-threat-
ening disease that requires immediate therapeutic interven-
tion. Early revascularization is the definitive treatment 
of acute coronary syndrome to limit infarct size (IS) and 
improve mortality. However, reperfusion of the ischemic 
myocardium itself can conversely worsen myocardial 
injury, which is known as myocardial ischemia–reperfusion 
injury [42]. Myocardial ischemia–reperfusion injury is a 
potentially preventable phenomenon that can be treated by 
both pharmacologic and non-pharmacologic interventions 
[32]. Murry et al. first demonstrated that brief episodes 
of non-lethal ischemia and reperfusion of the heart before 
sustained ischemia could limit myocardial IS in dogs. This 
cardioprotective effect was defined as ischemic precondi-
tioning (IPC) [62]. Subsequently, local IPC was applied for 
elective surgical procedures due to its clinical benefit [33]. 
This kind of cardioprotection can be induced by ischemic 
conditioning locally in the heart, as well as in tissues and 
organs remote from the heart. Remote ischemic condition-
ing can be induced before (pre-) or during (per-) ongoing 
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myocardial ischemia or after reperfusion (postconditioning), 
all of which have been shown to protect against myocardial 
ischemia–reperfusion injury in many experimental studies 
[12, 45, 46, 69]. However, the translation from animal exper-
iments to clinical situations for patients with acute myocar-
dial infarction has not been successful. In clinical trials of 
undergoing coronary artery bypass grafting, the cardiopro-
tective effects of remote ischemic conditioning have been 
contentious [28, 51, 60]. In some studies, remote ischemic 
conditioning was completely unable to improve clinical out-
comes in patients receiving primary percutaneous coronary 
intervention (PPCI) against myocardial infarction [18, 30, 
88]. These results that are contrary to those of experimental 
studies might be attributed to a variety of factors [16, 43, 
47, 89]. Therefore, it is quite possible that elucidation of the 
unexplained mechanism of remote ischemic conditioning 
will lead to clinical benefits.
The cardioprotective effect of remote ischemic condition-
ing reportedly involves humoral factors, neuronal signaling 
systems and their interaction [27, 48, 67]. Across species, 
humoral factors have been shown to be involved in activa-
tion of signal transduction [78]. As the humoral factors were 
characterized as having a size of < 12–14 kDa, and being 
hydrophobic, lyophilized and thermolabile, they were pre-
sumed to be a peptide or protein [38, 53, 74, 76]. The car-
dioprotective effect of remote ischemic conditioning is also 
based on the neuronal system, including the spinal cord, 
sympathetic and parasympathetic nervous systems [52, 59, 
86]. Several animal studies reported the important role of 
intactness of vagal nerve in the cardioprotective effect of 
remote ischemic conditioning [21, 61]. This phenomenon 
has been demonstrated by a previous study that showed that 
nitric oxide (NO) released by the stimulus of RIPC modu-
lates the secretion of acetylcholine from parasympathetic 
nerve via presynaptic activity [31]. In particular, the car-
dioprotective effect of remote ischemic conditioning was 
eliminated by sectioning of bilateral cervical vagal nerves 
and the posterior gastric branch of the vagal nerve [59, 86]. 
Additionally, interactions between the humoral factors and 
neuronal systems have been reported such as the relation-
ship between activation of the vagal nerve and glucagon-like 
peptide-1 (GLP) released from the gut as well as between 
vagal nerve and spleen [4, 5, 55, 65]. These results indicate 
that the mechanism may involve unknown humoral factors, 
vagal nerve activity and the visceral organs.
Ghrelin is a growth hormone-releasing peptide released 
by the stomach that exists in the circulation in two forms: 
acylated ghrelin (AG) and unacylated ghrelin (UAG) [39, 
49]. AG affects food intake and growth hormone secretion, 
whereas UAG does not. Total ghrelin concentration in cir-
culation is the sum of AG and UAG. Previous studies found 
that both AG and UAG have cardioprotective effects via the 
activation of certain cell signaling pathways [2, 40, 50, 81]. 
Some studies demonstrated a correlation between growth 
hormone family and remote ischemic conditioning via janus 
kinase (JAK)/signal transducer and activator of transcription 
(STAT) pathway [15, 48, 66]. However, it has never been 
proved whether ghrelin, which is released by the stomach in 
response to vagal activity, exerts its cardioprotective effects 
via activation of STAT in remote ischemic conditioning. We 
hypothesized that ghrelin might be one of the humoral fac-
tors involved in remote ischemic conditioning.
The aim of the present study was to elucidate whether or 
not ghrelin is one of the humoral factors contributing to the 
cardioprotective effects of remote ischemic preconditioning 
(RIPC). We focused on the secretion of ghrelin following the 
peripheral stimulus of RIPC procedures via acceleration of 
vagal activity. Furthermore, we investigated the association 
between the secreted ghrelin and activation of cell signaling 
pathways in cardiomyocytes.
Methods
Approval and preparation of animal experiments
All animal experiments and protocols were performed after 
the approval of the Institutional Animal Care and Use Com-
mittee of Sapporo Medical University (No. 17-117,118), and 
strictly adhered to the Guide for the Care and Use of Labora-
tory Animals (Institute for Laboratory Animal Research, 8th 
edition). Experiments were conducted in male Wistar rats 
aged 2–3 months. The rats were housed in our institutional 
animal facility in a temperature-controlled room (22–24 °C) 
under a 12-h light/12-h dark cycle with unlimited access to 
food and water.
Experimental protocol in vivo
Male Wistar rats were randomly assigned to the control 
(CON), RIPC, UAG, RIPC + AG490 (JAK2/STAT3 path-
way inhibitor) and UAG + AG490 groups (Fig. 1). Myo-
cardial ischemia–reperfusion injury was induced in all 
the rats in this in vivo model according to a previously 
described method, while they were positioned on a heating 
pad to maintain their body temperature at 37 °C [6, 77, 83]. 
Briefly, all the rats were anesthetized intraperitoneally with 
a mixture of three anesthetic agents, midazolam (2 mg/kg), 
butorphanol (2.5 mg/kg) and medetomidine (0.15 mg/kg), 
in accordance with previous reports [64]. Then, they were 
intubated with a 16-gauge cannula and were mechanically 
ventilated using a volume-controlled mode with the tidal 
volume set to 1 mL/100 g at a breath rate of 60 breaths/
min (Model 683 Small Animal Ventilator, Harvard Appara-
tus, Holliston, MA, USA). The tail vein was cannulated for 
drug infusion. Blood pressure was continuously monitored 
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through a cannula inserted into the left femoral artery. For 
assessment of echocardiograms (ECG) (lead II), needles 
were inserted subcutaneously into the anterior thorax. Myo-
cardial ischemia–reperfusion injury was established as fol-
lows. The left anterior descending (LAD) coronary artery 
was ligated using 6–0 polypropylene. Then, the heart was 
subjected to 30 min of ischemia followed by 120 min of rep-
erfusion. Successful myocardial infarction was confirmed by 
observation of pallor of the heart and apparent ST segment 
elevation on the ECG recorded by the PowerLab system 
(ADInstruments, Sydney, Australia). Rats in the CON group 
only underwent myocardial ischemia–reperfusion injury. In 
the RIPC group, RIPC procedures were performed on the 
right forelimb and hindlimb, with three cycles of ischemia 
for 5 min and reperfusion for 5 min, just before ligation of 
the LAD coronary artery. For RIPC, the right forelimb and 
hindlimb were encircled with neonatal blood pressure cuffs. 
The cuffs were inflated to 200 mmHg to achieve pallor of the 
limbs. In the UAG group, UAG (0.5 mcg/kg) (031-33, Phoe-
nix Pharmaceuticals, Belmont, CA, USA) was administered 
intravenously 30 min before the beginning of LAD coronary 
artery ligation. In the RIPC + AG490 and UAG + AG490 
groups, in addition to the RIPC or UAG administration, 
respectively, AG490 (3 mg/kg) (Abcam, Cambridge, MA, 
USA) was also intravenously infused 30 min before LAD 
ligation [22, 44]. Blood sampling was performed for the 
measurement of plasma concentrations of AG and UAG both 
pre and post the RIPC procedure, and before and 30 min 
after administration of UAG and/or AG490. The volume of 
blood collected at each sampling was 0.5 mL, samples being 
obtained from the cannulated left femoral artery. The same 
volume of normal saline was administered into the tail vein 
after each blood sampling. The blood samples were mixed 
with aprotinin and ethylenediaminetetraacetic acid to meas-
ure plasma levels of ghrelin. All the collected blood sam-
ples were centrifuged at 1500g at 4 °C for 15 min to extract 
the plasma, which was subsequently stored at − 80 °C for 
enzyme-linked immunosorbent assay (ELISA).
Infarct size determination
IS was assessed using a 1% 2,3,5-triphenyltetrazolium 
chloride (TTC) dying manner described in a previous study 
[7]. Briefly, at the end of the experimental protocols, LAD 
coronary artery re-occlusion was performed, and 4% Evans 
Blue was injected through the tail vein to determine the 
normal coronary flow region of the left ventricle (LV), in 
order to calculate the anatomic area at risk (AAR). Next, 
the heart was excised without pain for euthanasia, and the 
right atrium, right ventricular free wall and the adherent tis-
sue were removed. The LV was cut into 2-mm-thick slices 
and the slices were incubated in a 1% solution of TTC in 
phosphate-buffered saline (pH 7.4) for 15 min at 37 °C, fixed 
in 10% formalin for 20 min and photographed. The AAR and 
IS were evaluated in a blinded manner using a planimetry 
method and ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). The AAR and IS were expressed as 
percentages relative to LV area and AAR, respectively.
Fig. 1  Experimental protocol. All rats were subjected to 30  min of 
left anterior descending (LAD) coronary artery ligation followed by 
120  min of reperfusion. The control group (CON) only underwent 
myocardial ischemia–reperfusion. The remote ischemia precondition-
ing (RIPC) group received RIPC procedures (RPC) on two of their 
four limbs, which involved three cycles of 5 min ischemia and 5 min 
reperfusion. Rats in the unacylated ghrelin (UAG) group received 0.5 
mcg/kg of UAG administered intravenously 30 min before LAD coro-
nary artery ligation. Rats in the RIPC + AG490 and UAG + AG490 
groups received 3 mg/kg of AG490 intravenously in addition to the 
UAG injection or RIPC 30 min before LAD coronary artery ligation. 
At the end of the experimental protocol, hearts were collected and 
infarct size was assessed using 1% 2,3,5-triphenyltetrazolium chlo-
ride staining. CON, control group; RIPC, remote ischemic precon-
ditioning; RPC, remote ischemic preconditioning procedures; UAG, 
unacylated ghrelin; AG490, JAK2/STAT3 pathway inhibitor
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Measurements of AG and UAG concentrations
Plasma concentrations of both AG and UAG were deter-
mined using the ELISA method and a commercially avail-
able kit (LSI Medience, Tokyo, Japan). Data evaluations 
were performed spectrophotometrically using a standard 
96-well plate reader at a 450 nm wavelength (Sunrise™ 
reader, Tecan Group Ltd., Männedorf, Switzerland).
Western blotting
We examined the modulation of phosphorylation of 
 STAT3tyr705, which may play a crucial role in the cardio-
protective effects of RIPC and UAG, as in previous studies 
in pigs [36, 55, 78]. For this, left ventricular apex tissue 
was sampled at two time points: just prior to ischemia and 
10 min after reperfusion from separate rats. The rats were 
euthanized after collection of the myocardial tissue. Total 
protein was extracted with ice-cold buffer, and the concen-
trations of protein were detected with a BCA Protein Assay 
Kit (Thermo Fisher Scientific, Waltham, MA, USA) [41]. 
Western blotting was performed as described previously 
[90]. Briefly, equal amounts of proteins were separated 
by 7.5–12.5% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a nitrocel-
lulose membrane (Bio-Rad Laboratories, Hercules, CA, 
USA). After blocking, the membranes were incubated with 
antibodies directed against STAT3 (#12640, 1:1000; Cell 
signaling Technology, Beverly, MA, USA) and the phospho-
rylated forms of  STAT3tyr705 (#9138, 1:1000; Cell signaling 
Technology, Beverly, MA, USA). All blots were analyzed 
in a blinded manner.
Statistical analysis
Based on a previous study, a sample size of six rats in each 
group was deemed necessary to detect a 25% reduction 
in IS, which was considered to be appropriate (α = 0.05, 
1  − β = 0.8, two-tailed) and clinically effective by the 
G*Power 3.1 statistical power analysis program (Heinrich-
Heine-University, Düsseldorf, Germany) [8]. All data were 
tested for normal distribution using the Shapiro–Wilk test. 
Data are presented as mean ± standard error of the mean 
(SEM). AAR, IS and ratio of total STAT3 and phospho-
rylation of  STAT3tyr705 among all groups were analyzed 
using one-way analysis of variance (ANOVA) followed 
by the Tukey post hoc test. The levels of AG and UAG in 
the plasma at different time points and hemodynamic sta-
tus were analyzed by two-way ANOVA for repeated meas-
ures (protocol, time). All statistical analyses of data were 
performed using GraphPad Prism 7.0 software (GraphPad 
Software, La Jolla, CA, USA). Statistical differences were 
considered significant at a value of P < 0.05.
Results
Hemodynamic status
The rats’ hemodynamic status is shown in Table 1. There 
were no significant differences in HR between the five 
Table 1  Hemodynamic status 
of the rats
Data are shown as mean ± standard error of the mean (SEM)
HR, heart rate; CON, control group; RIPC, remote ischemic preconditioning group; UAG, unacylated ghre-
lin; AG490, JAK2/STAT3 pathway inhibitor; MBP, mean blood pressure





 CON 258.6 ± 8.5 290.0 ± 8.9 272.9 ± 12.7 316.0 ± 15.0
 RIPC 286.6 ± 26.6 246.6 ± 9.6 230.1 ± 13.3 245.3 ± 28.4
 UAG 266.6 ± 18.6 272.8 ± 20.9 276.0 ± 10.9 317.0 ± 15.3
 RIPC + AG490 296.6 ± 9.4 281.3 ± 15.9 291.0 ± 14.6 305.4 ± 16.9
 UAG + AG490 265.0 ± 19.9 279.6 ± 23.8 289.1 ± 17.5 310.9 ± 29.2
MBP (mmHg)
 CON 137.9 ± 3.9 96.9 ± 7.0* 66.9 ± 4.3* 64.9 ± 2.6*
 RIPC 117.2 ± 4.4 76.9 ± 10.7* 58.0 ± 7.1* 58.4 ± 7.0*
 UAG 148.1 ± 5.3 94.6 ± 7.1* 64.9 ± 2.8* 69.9 ± 4.1*
 RIPC + AG490 123.0 ± 6.9 83.3 ± 11.3* 65.7 ± 2.9* 63.4 ± 3.3*
 UAG + AG490 123.1 ± 5.5 83.7 ± 6.2* 66.0 ± 2.3* 69.9 ± 2.1*
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groups at baseline, and during ischemia and reperfu-
sion. However, MBP decreased compared to baseline during 
ischemia and reperfusion in all groups (P < 0.05).
Area at risk and Infarct size
The area at risk was not significantly different between 
all groups (CON: 57.4% ± 2.4%, RIPC: 55.8% ± 2.3%, 
UAG: 54.7% ± 1.9%, RIPC + AG490: 57.9% ± 1.5%, 
UAG + AG490: 60.5% ± 2.1%, Fig.  2). IS was signifi-
cantly reduced in the RIPC and UAG groups, as compared 
to that in the CON group (CON: 54.1% ± 4.2%, RIPC: 
34.2% ± 3.6%, UAG: 33.8% ± 2.7%, P < 0.05 Fig. 3), while 
it remained similar to control levels in the RIPC + AG490 
and UAG + AG490 groups (RIPC + AG490: 54.6% ± 5.0%, 
UAG + AG490: 55.0% ± 3.5%).
Plasma levels of acylated and unacylated ghrelin
Baseline levels of AG and UAG were comparable 
among groups. In all except the CON group, plasma lev-
els of UAG were significantly increased by RIPC or 
UAG administration compared to the respective base-
line levels (CON pre: 1,370.6 ± 53.5 pg/mL, CON post: 
2,003.9 ± 83.8  pg/mL, RIPC pre: 1,626.6 ± 86.3  pg/
mL, RIPC post: 2,681.6 ± 355.1  pg/mL, UAG pre: 
1,653.7 ± 132.9  pg/mL, UAG post: 2,864.0 ± 288.9  pg/
mL, RIPC + AG490 pre: 1,504.5 ± 191.1  pg/mL, 
RIPC + AG490 post: 2,460.2 ± 279.2 pg/mL, UAG + AG490 
pre: 1,354.9 ± 173.1  pg/mL, UAG + AG490 post: 
2,550.6 ± 117.0  pg/mL, P < 0.05, Fig.  4). There were, 
however, no significant differences in plasma levels of AG 
among the groups (Online resource. 1).
Western blotting
STAT3tyr705 phosphorylation 10 min after reperfusion was 
higher than that after the experimental procedures in RIPC 
and UAG groups, but not in the other groups (P < 0.05, 
Fig. 5 and Online resource 2). Thus, phosphorylation of 
 STAT3tyr705 protein 10 min after reperfusion was abolished 
by administration of AG490. Additionally, phosphorylation 
of  STAT3tyr705 protein 10 min after reperfusion in RIPC 
group was significantly higher than that in UAG group.
Discussion
We showed that RIPC procedures increase plasma UAG 
levels and protect against myocardial ischemia–reperfusion 
injury via phosphorylation of  STAT3tyr705. Furthermore, we 
confirmed that the increase in plasma UAG levels resulting 
from administration of 0.5 mcg/kg UAG had similar car-
dioprotective effects as RIPC. It has previously never been 
demonstrated whether ghrelin exerts its RIPC-induced car-
dioprotective effects via activation of the STAT pathway. 
The present study indicated that UAG might be a crucial 
humoral factor in the cardioprotective effects of RIPC.
Fig. 2  Area at risk of infarction in the five groups. The area at risk 
is presented as a percentage relative to the area of the left ventri-
cle. Data are shown as mean % ± SEM, n = 8–10 rats per group. Anal-
ysis by one-way ANOVA followed by Tukey post hoc test revealed no 
significant differences between groups. CON, control group; RIPC, 
Remote ischemic preconditioning group; UAG, unacylated ghrelin; 
AG490, JAK2/STAT3 pathway inhibitor
Fig. 3  Infarct size in the five groups. Infarct size is presented as 
a percentage relative to the area at risk. Data are shown as mean 
% ± SEM, n = 8–10 rats per group. *P < 0.05 vs. CON, †P < 0.05 vs. 
RIPC + AG490, ‡P < 0.05 vs. UAG + AG490,  by one-way ANOVA 
followed by Tukey post hoc test. CON, control group; RIPC, Remote 
ischemic preconditioning group; UAG, unacylated ghrelin; AG490, 
JAK2/STAT3 pathway inhibitor
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Many researchers have tried to reveal the complex mecha-
nisms involved in remote ischemic conditioning. They found 
that the mechanism is very complex and involves humoral 
factors, neuronal systems and their interactions [9, 59, 63, 
67, 91]. Various experimental studies have shown different 
results and outcomes depending on species differences [3, 
55, 61]. Therefore, the factors based on the mechanisms of 
remote ischemic conditioning are both common and con-
troversial between animal species. Some studies in rodents 
and humans found that endothelium-derived NO produced 
peripherally by the stimulus of RIPC, which exists into cir-
culation as nitrite, mediates the cardioprotective effect by 
Fig. 4  Plasma concentrations of UAG in the five groups. Blood sam-
ples in each group were collected both before and after the RIPC 
procedure, and before and 30 min after administration of UAG and/
or AG490. Data are shown as mean (pg/mL) ± SEM, n = 8–10 rats 
per group. *P < 0.05 vs. the ‘pre’ period in each group, as assessed 
by two-way ANOVA followed by Tukey post hoc test. CON, con-
trol group; RIPC, Remote ischemic preconditioning group; UAG, 
unacylated ghrelin; AG490, JAK2/STAT3 pathway inhibitor; pre, 
before RIPC or drug administration; post, 30 min after RIPC or drug 
administration
Fig. 5  Ratio of phosphoryl-
ated STAT3 and total STAT3 
in rat myocardium sampled 
from the left ventricular apex 
pre-ischemia and after 10 min 
of reperfusion among the five 
groups. Data are shown as 
mean ± SEM, n = 4 per group. 
*P < 0.05 vs. ‘pre’ in each 
group, assessed by one-way 
analysis of variance (ANOVA) 
followed by Tukey post hoc 
test. †P = 0.0112 assessed by 
one-way ANOVA followed 
by Tukey post hoc test. CON, 
control group; RIPC, Remote 
ischemic preconditioning group; 
UAG, unacylated ghrelin; 
AG490, JAK2/STAT3 pathway 
inhibitor; pre, before RIPC or 
drug administration; rep10, 
10 min after reperfusion in the 
left anterior descending coro-
nary artery
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NO transfer into the cardiomyocytes [1, 14, 70, 75]. Indeed, 
NO serves RIPC cardioprotection as one of the humoral fac-
tors in rodents and humans, but not in pigs and rabbits [10, 
68]. The neuronal systems of remote ischemic conditioning 
are mainly composed of sympathetic and parasympathetic 
nerves and the spinal cord [4, 27, 52, 57, 59, 86]. In par-
ticular, several experimental studies reported the important 
role of an intact vagal nerve underling the cardioprotec-
tive effect of RIPC [3, 21, 61, 71, 86]. These studies were 
supported by the evidence that NO promotes acetylcholine 
release from parasympathetic nerve fibers via presynaptic 
activation [31]. Although interactions between the humoral 
factors and neuronal systems have been reported such as 
the relationship between the vagal nerve and GLP-1 in rats, 
some studies indicated that there are no GLP-1 receptors on 
cardiomyocytes and that GLP-1 does not activate the cardiac 
vagal nerves [4, 5, 65, 74, 76]. On the other hand, Lieder 
HR et al. demonstrated that the cardioprotection of RIPC is 
based on the interaction between the vagal nerve and spleen 
in pigs and rats [55]. Interestingly, they found that vagotomy 
with RIPC in pigs did not eliminate the reduction in IS at 
all, and that the spleen critically releases humoral factors 
through vagal nerve-induced acetylcholine release. Some 
studies showed that the cardioprotective effect of RIPC was 
eliminated by sectioning of the vagal nerve in the neck bilat-
erally and of the posterior gastric branch of the vagal nerve 
in rabbits and rats [13, 59, 67]. A previous study addition-
ally found that electrical stimulation of the posterior gas-
tric branch of the vagal nerve imitated the cardioprotective 
effect of RIPC in rats [59]. This study suggested that the 
visceral organs innervated by the posterior gastric branch 
of the vagal nerve can produce and release humoral factors. 
However, the vagal nerve-linked humoral factors released by 
the stomach that contribute to RIPC-induced cardioprotec-
tion have not been determined. Our study focused on ghrelin 
as the potential humoral factor, since ghrelin is derived from 
gastric parietal cells via NO vagal nerve-induced acetylcho-
line release and might have cardioprotective effects against 
myocardial ischemia–reperfusion injury [59, 84]. The pre-
sent study showed that the plasma concentrations of UAG, 
but not AG, were significantly elevated with RIPC proce-
dures. In fact, previous studies have reported the association 
between ghrelin and vagal afferents [85, 87]. Veedfald et al. 
found that the total ghrelin concentration in vagotomized 
patients was decreased compared to that in patients with 
intact vagal innervation and after indirect vagal stimulation 
with food intake [85]. Williams et al. showed that the total 
ghrelin concentration in vagotomized or muscarine receptor 
blocker-administered rats was not increased compared to that 
in rats with intact vagal innervation under 48 h of food depri-
vation [87]. Thus, the secretion of ghrelin was suppressed by 
vagotomy or systemic administration of muscarinic receptor 
blockers. These studies might support the present hypothesis 
that NO released by the peripheral stimulus of RIPC acceler-
ates activation of the intact vagal nerve leading to secretion 
of ghrelin into circulation via the release of acetylcholine. 
The present study found that the similarly increased concen-
trations of UAG after UAG administration also had cardio-
protective effects against myocardial ischemia–reperfusion 
injury, indicating that ghrelin might be one of the humoral 
factors involved in the cardioprotection of RIPC, which, in 
turn, is mediated by vagal afferent nerves. While UAG is 
likely to have cardioprotective effects in RIPC, further stud-
ies are needed to reveal the association between modulation 
of UAG, but not AG, with RIPC and vagal nerve activity.
We observed that  STAT3tyr705 phosphorylation might be 
a common cell signaling pathway with both RIPC and UAG. 
A previous study showed  STAT3tyr705 has a causal role of 
the cardioprotection and mitochondrial function [36]. Some 
previous studies showed that RIPC activates the STAT3 
pathway for its cardioprotective effects across species [29, 
78]. Similarly, there are some reports describing the cardio-
protective effects of UAG [24, 25, 66]. Although the receptor 
of UAG has not been identified, a previous study found that 
UAG could protect against doxorubicin-induced cardiomy-
opathy through growth hormone secretagogue receptor-1a 
(GHSR1a)-independent pathway, which is a JAK2/STAT3 
cell signaling pathway [66]. Other studies showed that UAG 
and AZP-531, a fragment from native UAG, protect against 
myocardial ischemia–reperfusion injury in mice, and found 
that UAG could increase coronary perfusion via NO release 
and activation of the phosphorylation of extracellular signal-
regulated kinase 1/2 and protein kinase B at coronary artery 
endothelial cells in pigs [24, 25]. We demonstrated that the 
increased plasma levels of UAG with both RIPC and UAG 
injection protected against myocardial ischemia–reperfusion 
injury through activation of the JAK2/STAT3 pathway, as 
was also previously shown. In another study, Lieder et al. 
demonstrated that RIPC procedures phosphorylate myocar-
dial  STAT3tyr705 in pigs with or without vagotomy, and that 
the spleen plays an important role in the cardioprotective 
signaling transduction of RIPC in pigs and rats [55]. They 
found that STAT activation is not sufficient for RIPC cardio-
protection but may be required in pigs so well. In fact, their 
study found that vagotomy with RIPC did not reduce IS in 
pigs at all. Their results may be attributed to their using large 
mammals. The vagal tone of rodents differs from that of 
larger mammals [3, 4, 61]. The heart rate of larger mammals 
is usually slower than that of smaller animals [82]. Further, 
it has not been proven whether or not vagotomized rodents 
with and without RIPC demonstrate activation of the JAK/
STAT pathway. Therefore, it may be difficult to compare 
rodent studies with pig studies. The present study found that 
 STAT3tyr705 phosphorylation was associated with the car-
dioprotection of both RIPC and UAG in rats. Many studies 
have investigated various cell signaling pathways in RIPC 
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and UAG in addition to the JAK/STAT pathway, such as 
the reperfusion injury salvage kinase (RISK) pathway [78]. 
Further studies are needed to demonstrate whether or not 
UAG administration activates other cell signaling pathways.
In the present study, we used 0.5 mcg/kg UAG for 
assessing its cardioprotective effects. However, no report 
has assessed the cardioprotective effects of a UAG dose 
of < 100 mcg/kg. Although some studies noted cardio-
protective effects of high doses of UAG (100, 1000 mcg/
kg and 100 nmol/kg, which is almost equal to 319 mcg/
kg), they did not measure the resultant plasma concentra-
tions of UAG [25, 40, 66]. In a preliminary study, we also 
assessed high UAG doses as in previous studies. Although 
the dose administered provided cardioprotection against 
myocardial ischemia–reperfusion injury, plasma levels of 
UAG after 100 mcg/kg UAG administration were too high 
to be measured by the ELISA kit (data not shown). Thus, 
it seems that while the high doses in previous studies have 
cardioprotective effects on myocardial ischemia–reperfu-
sion injury, the dosage is not physiological and cannot be 
applied in clinical situation. Based on the results of the pre-
liminary dose study, we investigated the effects of various 
small doses of UAG (0.25, 0.5, 1, 2, 20 and 30 mcg/kg) 
on myocardial ischemia–reperfusion injury. We found that 
all the doses of UAG administered resulted in significant 
increases in plasma concentrations of UAG compared to 
baseline, along with reduction in IS except for the group 
of 0.25 mcg/kg administration, although the ELISA kit was 
unable to measure plasma levels of UAG after 20, 30 mcg/
kg UAG administration (Online resource 3, 4, 5). Therefore, 
0.5 mcg/kg UAG administration was adopted in the present 
study, since the plasma concentration of UAG after 0.5 mcg/
kg UAG administration was almost equal to the concentra-
tion of UAG after the RIPC procedure within physiologi-
cal variance. Furthermore, these results suggested that the 
plasma concentration of UAG resulting from 0.5 mcg/kg 
UAG administration could simulate the cardioprotective 
effects of RIPC via activation of the JAK2/STAT3 pathway.
A number of studies reported the humoral factors 
involved in RIPC, such as, autacoids, hormones, cytokines, 
chemokines, neuropeptides, amino acids and ribonucleic 
acid [9, 17, 23, 48, 56, 73, 80]. UAG has characteristics 
in common with several of the humoral factors in terms of 
molecular size, hydrophobicity, lyophilization and thermola-
bility [76]. The humoral factors were characterized as having 
a size of < 12–14 kDa [38, 53, 58, 74, 76]. UAG is a type of 
peptide hormones and almost 3188 Da in size. Furthermore, 
a previous study found that circulating AG and UAG are 
hydrophobic in nature [79]. On the basis of these studies, 
UAG has the appropriate biophysical characteristics to func-
tion as a cardioprotective humoral factor in RIPC.
There is much evidence related to the cardioprotec-
tion of remote ischemic conditioning against myocardial 
ischemia–reperfusion injury in experimental studies [12, 46, 
63, 67, 91]. However, the translation from animal experi-
ments to clinical situations for acute myocardial infarction 
cannot be going well and there are still several additional 
issues that need to be overcome. This problem can be attrib-
uted to the radically different backgrounds of the subjects 
in each study. While many experimental studies are con-
ducted using healthy young animals with no comorbidities, 
clinical trials in patients suffering from acute coronary syn-
drome vary in terms of several factors, such as the patients 
background, trial protocol, anesthetic conditions, age, sex, 
comorbidities and comedication, which can attenuate the 
cardioprotective effects of remote ischemic preconditioning 
[6, 11, 18, 26, 28, 30, 35, 51, 54, 60, 88]. In addition, the 
myocardial cell signaling pathways in rodents and humans 
are different [19, 20, 37, 55, 78]. Although these are the 
current problems that need to be overcome for translation 
of RIPC cardioprotection to humans, it is quite possible that 
elucidation of the unknown mechanisms of remote ischemic 
conditioning will be clinically beneficial. No experimental 
studies on the association between RIPC and ghrelin have 
been investigated. The present study found that the periph-
eral stimulus of RIPC led to secretion of UAG from the 
stomach, and that UAG prevented myocardial reperfusion 
injury through  STAT3tyr705 activation in rats.
In summary, the present study demonstrated that RIPC 
procedures increased plasma levels of UAG to a similar level 
as that resulting from administration of 0.5 mcg/kg UAG 
administration, both of which exerted their cardioprotective 
effects in rats through STAT3 phosphorylation. Our data 
provide new evidence that UAG is one of the key humoral 
factors in the cardioprotective effects of RIPC.
Study limitation
There are some limitations to this study. First, the valid-
ity of our studies might be inadequate because we did not 
investigate the cardioprotective effects of UAG in the pres-
ence of a UAG inhibitor. Future studies using a UAG inhibi-
tor are desired. However, so far, the receptor of UAG has 
not been identified, and UAG inhibitors are unavailable. 
Second, we conducted this animal study under anesthesia 
with three anesthetic agents, midazolam, butorphanol and 
medetomidine. Previous animal studies were conducted 
using pentobarbital, sevoflurane, propofol, etc. [7, 8]. Those 
studies found that the cardioprotective effects of RIPC in rats 
were abolished by propofol anesthesia, which also inhib-
ited release of the humoral factors of RIPC [7, 8]. These 
results indicate that the cardioprotective effects might be 
modulated by the type of anesthetic agents. In future, we 
should compare plasma levels of UAG under volatile and/or 
propofol anesthesia. Thirdly, the validation of  STAT3tyr705 
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phosphorylation might not be sufficient. The methods used 
in the present study differed from those of previous studies 
in terms of the method of sampling myocardial tissues [20, 
36, 55, 78]. In this study, we verified the phosphorylation of 
STAT3 using the discontinuous rat myocardium samplings, 
obtaining samples just before ischemia and 10 min after 
reperfusion from separate animals. In previous studies, on 
the other hand, myocardium samples in both and humans 
were sequentially obtained just before ischemia and 10 min 
after reperfusion. Although it is difficult to directly compare 
the present study with previous studies, our data of Western 
blots, which using not sequential samplings in rat, were simi-
lar to the results of previous studies in pigs with sequential 
samplings. Finally, additional work is needed to determine 
the mechanism by which plasma concentration of UAG is 
increased in RIPC, but not AG, is increased with RIPC.
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